Cost Analysis of Interventions for Antimuscarinic Refractory Patients With Overactive Bladder

How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study

Ian Milsom, Paul Abrams, L. Cardozo et al. · British Journal of Urology · 2001 · 1.8K citations · Full text

Medicine, Internal Medicine, Urology +13

BOTULINUM TOXIN TYPE A IS A SAFE AND EFFECTIVE TREATMENT FOR NEUROGENIC URINARY INCONTINENCE: RESULTS OF A SINGLE TREATMENT, RANDOMIZED, PLACEBO CONTROLLED 6-MONTH STUDY

Brigitte Schurch, Marianne de Sèze, P. Denys et al. · The Journal of Urology · 2005 · 579 citations

Medicine, Pharmacotherapy, Urology +17

Comparing Adherence and Persistence Across 6 Chronic Medication Classes

Jason Yeaw, Joshua S. Benner, John G. Walt et al. · Journal of Managed Care Pharmacy · 2009 · 552 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Estimated economic costs of overactive bladder in the United States

Teh-wei Hu, Todd H. Wagner, Judith D. Bentkover et al. · Urology · 2003 · 265 citations

Medicine, Pharmacoeconomics, Urology +11

Experience With 100 Cases Treated With Botulinum-A Toxin Injections in the Detrusor Muscle for Idiopathic Overactive Bladder Syndrome Refractory to Anticholinergics

Daniel M. Schmid, P. Sauermann, Mads U. Werner et al. · The Journal of Urology · 2006 · 257 citations

Medicine, Pharmacotherapy, Urology +16